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Abstract In a randomized, open-label, controlled, multicentre study, the clinical and bacteriological efficacy, safety
andtolerabilityoforalgemifloxacin (320mgoncedaily,5 days)wascomparedwith sequentialintravenous (i.v.)ceftriaxone
(1g once daily, maximum 3 days) followedbyoral cefuroxime axetil (500mg twice daily, maximum 7 days) in adult hospi-
talizedpatientswith acute exacerbationsofchronicbronchitis (AECB) (n= 274).The clinical successrates atfollow-up (21^
28 dayspost-therapy) inthe clinicalper-protocolpopulation (theprimaryendpoint) were 86.8% (105/121) forgemifloxacin
vs.81.3% (91/112) for ceftriaxone/cefuroxime (treatmentdifference = 5.5,95% CI 3.9,14.9).The corresponding clinical re-
sults in the clinical intention-to-treat (ITT) population were 82.6% (114/138) vs. 72.1% (98/136), respectively (treatment
difference = 10.5,95% CI 0.7, 20.4).Thus, gemifloxacinhad significantlyhigherclinical success rates than ceftriaxone/cefur-
oxime.Themediantimeto dischargewas 9 daysinthe gemifloxacin group vs.11days inthe ceftriaxone/cefuroximegroup
(P = 0.04,Wilcoxon test). At follow-up,120/138 (87.0%) gemifloxacin-treated patients had been discharged fromhospital,
compared with 111/136 (81.6%) ceftriaxone/cefuroxime-treated patients in the clinical ITT population. Both treatments
were generally well tolerated and therewas no significantdifference between the treatment groups in the incidence or
type of adverse eventsreported.A 5-daycourse oforalgemifloxacinwas shownby this study tobe at leastequivalentto
sequential i.v. ceftriaxone/cefuroxime axetil (for up to 10 days) in patients with AECB who require hospital treatment.
r 2002 Elsevier Science Ltd.Allrights reserved.
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Chronic bronchitis is a common condition which has
acute exacerbations (AECB) characterized by increased
severity of symptoms and purulent sputum (1). In the
U.S.A., the incidence of chronic bronchitiswas estimated
at 54 cases per1000 population (i.e. more than14million
people) in 1994, and treatment was sought in 90.9% of
AECB episodes (2). Incidences are higher in older per-
sons (3).The predominant bacterial pathogen implicatedReceived 8 April 2002, accepted in revised form 20 August 2002
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E-mail: r.wilson@rbh.nthames.nhs.ukin AECB is Haemophilus in£uenzae, which is present in
over 50% of all bacteriological exacerbations, with ap-
proximately a further third of isolates being either Strep-
tococcus pneumoniae orMoraxella catarrhalis (1). As most
antimicrobial therapy is empirical, it is important that
the choice of agent and dosing regimen cover the most
commonbacterial aetiologies (4,5). Additionally, the pos-
sible involvement of antimicrobial-resistant pathogens
must be considered (5).
Maintaining e¡ective patient care whilst managing es-
calating healthcare costs is a continuing priority, particu-
larly in the hospital sector where the costs per patient
aregenerally far higher than in the community (2). In par-
ticular, prevention of admission and reduction of the
length of time patients remain in hospital are major
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nous (i.v.) to oral switch therapy is a strategy aimed at
reducing the costs of extended parenteral treatment,
whilemaintaining the e¡ectiveness of antibacterial ther-
apy (8). In addition, conversion to oral therapygreatly re-
duces the risk of infection through i.v. linesFa
signi¢cant source of bacteraemia (9). The merits of se-
quential therapy in AECB have been demonstrated in a
number of studies (10). It is anticipated that the use of
an e¡ective oral agent from the outset of therapymight
reduce hospitalizations and bring further bene¢ts in
terms of reduction in length of hospital stay, cost reduc-
tion, convenience to patients and the elimination of i.v.
line infection.
Grossman (11,12) has strati¢ed antibiotic treatment
based on chronic obstructive pulmonary disease sever-
ity, co-morbidity and the severity of the exacerbation,
and he suggests that, in order to maximize clinical cure
in hospitalized patients or the very ill, antimicrobial-
resistant strains should be covered and he includes
third-generation cephalosporins and quinolones as re-
commended treatments for this patient group.
Gemi£oxacin is an advanced-generation, enhanced-
a⁄nity quinolone with potent activity against the major
pathogens in AECB, including strains resistant to other
agents (13,14).Clinical studies of gemi£oxacin in the treat-
ment of AECB in the community setting have con¢rmed
that it iswell tolerated, has a favourablepharmacokinetic
pro¢le and has high clinical and bacteriological e⁄cacy
(15^18). In particular, in a subset of evaluable patients,
gemi£oxacin eradicated H. in£uenzae from the sputum
after one dose of therapy (17).These studies indicate the
potential utility of gemi£oxacin in severe AECB.The cur-
rent study was performed to compare the e⁄cacy and
safety of oral gemi£oxacin for 5 days with those of se-
quential i.v. ceftriaxone and oral cefuroxime axetil
(19,20) for up to 10 days in hospitalized AECB patients
who might normally be expected to receive parenteral
therapy as initial treatment.
MATERIALSANDMETHODS
Patients
To be eligible for enrolment into the trial, patients were
required to have a history of chronic bronchitis, with
cough and sputum production for over 2 consecutive
years and formostdays in a consecutive 3-month period.
Patients were also required to have at least one of the
following: FEV1 o50%, age 465 years, 4 episodes of
AECB in the past year requiring antibacterial therapy,
known cardiorespiratory co-morbidity or three co-
morbidity markers from within cardiovascular, muscu-
loskeletal, central nervous system, endocrine, haemato-
logic or hepatic systems. Adulthospitalizedpatients aged
at least 40 years with AECB characterized by increasedcough, purulent sputum and dyspnoea and considered
under normal circumstances to be appropriate for par-
enteral therapy were included in the study. Patients had
to supply written, informed consent and be willing and
able to comply with the study protocol. All female pa-
tients of child-bearing potential had to have a negative
urine pregnancy test before enrolment. Patients were
excluded from the study if they had suspected hypersen-
sitivity to study treatments or were receiving (i) poten-
tially interacting drugs; (ii) any investigational drug,
vaccine or device within 30 days or 5 half-lives prior to
screening; (iii) any other antibacterial agentwithin 7 days
prior to randomization (except o24h of antibacterial
therapy within 24h prior to randomization for the cur-
rent exacerbation); (iv) systemic steroids for41month
at a dose of 430mgday1 prednisone (or equivalent);
or (v) 430mgday1 of prednisone during the study. In
addition, standard exclusion criteria relating to preg-
nancy, the presence of underlying disease or infection
that would compromise the e⁄cacy evaluation and
accepted ranges for clinical laboratory test parameters
were applied.
Study design
This was a randomized (1:1), open-label, controlled, mul-
ticentre study comparing the clinical and bacteriological
e⁄cacy, safety and tolerability of oral treatment with
gemi£oxacin (320mg once daily for 5 days) vs. sequential
therapy with parenteral ceftriaxone (1g i.v. administered
once daily over a period of 30min for a maximum of
3 days) followed by oral treatment with cefuroxime
(500mg twice daily for a maximum of 7 days) in hospita-
lized adult patients with moderate-to-severe AECB.
Patients were assessed at four visits: screening (Day 0),
on-therapy (Days 2^4), end of therapy (2^4 days post-
therapy) and follow-up (21^28 days post-therapy).
The primary e⁄cacy parameter was clinical response
(success or failure) at follow-up. Secondarye⁄cacy para-
meters included clinical response at the end of therapy,
bacteriological response at the end of therapy and fol-
low-up and time to discharge from hospital. The study
was conducted in accordance with Good Clinical Prac-
tice Guidelines and the revised Declaration of Helsinki
(amended in Somerset West, South Africa, 1996). The
protocol and statement of informed consent were ap-
provedby an Institutional Review Board (or Ethics Com-
mittee) at each centre prior to study start.
Clinical evaluation
The signs and symptoms of AECB were used by the in-
vestigator to evaluate clinical outcome at the end of
therapy and follow-up (Table 1). The clinical response,
based on clinical outcome, was either success or failure
(an outcome of failure at the end of therapy or
TABLE 1. Criteria for evaluatingclinical outcome
Visit Clinical outcome Criteria
End oftherapy (visit 3,
2^4 dayspost-therapy)
Clinical success Su⁄cient improvement or resolution of the signs and symptoms of AECB
recorded at screening suchthat no additional antibacterial therapywasin-
dicated for AECB
Clinical failure Insu⁄cient improvementordeterioration of signs and symptoms of AECB
recorded at screening such that additional antibacterial therapy was
indicated for AECB
Unable to
determine
An assessmentof clinical outcome couldnot bemade
Follow-up (visit 4, 21^28 days
post-therapy)
Follow-up
clinical success
Sustained improvement or resolution of signs and symptoms of AECB for
patients whowere clinical successes at the end-of-therapy visit, such that
no additional antibacterial therapywas indicated for AECB
Clinical
recurrence
Reappearance or deterioration of signs and symptoms of AECB for pa-
tientswhowere clinical successes atthe endoftherapy, suchthat additional
antibacterial therapywas indicated for AECB
Unable to
determine
An assessmentof clinical outcome couldnot bemade
Note:For thosepatientswithdrawingprior tothe end-of-therapy visit, evaluationoftheirclinicaloutcomewasdeterminedatthe
time of withdrawal.
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Clinical failure at the endof therapy was carried forward
to follow-up as failure.
Bacteriological evaluation
Sputum samples were taken prior to the ¢rst dose of
study medication (Day 0) and, where possible, at the
end of therapy and follow-up. Samples were also taken
at the on-therapy visit for patients whowithdrew at this
time. Sputum samples were assessed for purulence at
the local laboratory in each country participating, with
evaluable samples required to have 425 white blood
cells per ¢eld ando10 squamous epithelial cells at100
magni¢cation.Gram staining, culture and, if required for
clinical guidance, susceptibility testing were conducted
at the local laboratory and isolates were then sent to
the central laboratory for further testing. All suscept-
ibility testing was performed according to National
Committee for Clinical Laboratory Standards (NCCLS)
guidelines (21,22).
Per-patient bacteriological response (success or fail-
ure) was based on the per-pathogen bacteriological out-
come and de¢ned as follows at the end of therapy:
successFeradication of all initial pathogens from spu-
tum or presumed eradication (the patient was a clinical
success andunable to provide a sputum sample), without
superinfection (isolation of a new pathogen in a patient
with clinical failure), but with or without colonization
(isolation of a newpathogen in a patientwith clinical suc-
cess); failureFpersistence of an initial pathogen in spu-
tum or presumed persistence (the patient was a clinical
failure and unable to provide a sputum sample), a super-infection, or an assessment of unable to determine (an
assessment of bacteriological outcome could not be
made) for one ormore initial pathogens.Per-patient bac-
teriological response at follow-up was de¢ned similarly.
Bacteriological failure included recurrence of one or
more of the initial pathogens at follow-up (recurrence
at follow-up of a pathogen eliminated at the end of ther-
apy), a new infection (isolation of a newpathogen in a pa-
tientwith clinical recurrence), an assessmentof unable to
determine for one ormore initial pathogens, or a bacter-
iological response of failure at the end of therapy.
Safety
Allpatientswhoreceived at leastone dose of studymed-
icationwere included in the safety population.Vital signs
were assessed at all study visits. Haematology and clini-
cal chemistry tests were performed at the screening,
on-therapy and end-of-therapy visits, electrolytes were
measured at the on-therapy visit and creatinine clear-
ance at screening. For patients in countries where ap-
proval was obtained for this protocol amendment, an
electrocardiogram (ECG) was performed at screening
and at the on-therapy visit, 2^4h after themorning dose
of oral drug or on completion of i.v. infusion.The change
inQTcwas assessedrelative to thenormalrange accord-
ing to CPMP guidelines (23): signi¢cant change o¡-
therapy to on-therapy of 460ms, signi¢cant absolute
value of4500ms.
Signs and symptoms occurring or changing in the
7 days before the start of study medication were
recorded. Adverse events (AEs) were recorded from
the start of therapy up to 30 days post-therapy and
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Statistical evaluation
Four patient populations were de¢ned for the purposes
of analysis: clinical intention to treat (ITT)Fall rando-
mized patients; clinical per-protocol (PP)Fall rando-
mized patients who satis¢ed the inclusion/exclusion
criteria and who subsequently adhered to the protocol;
bacteriology ITTFall randomized patients who had at
least one pathogen identi¢ed at screening; bacteriology
PPFthose patients in the bacteriology ITT population
who satis¢ed the inclusion/exclusion criteria and who
subsequently adhered to the protocol.The primary e⁄-
cacy analysis used two-sided 95% con¢dence intervals
(CIs) to estimate the di¡erence in the proportion of suc-
cesses between the treatment groups. A conclusion of
non-inferior e⁄cacy of gemi£oxacin was drawn if the
lower limit of the con¢dence interval (gemi£oxacin
minus ceftriaxone/cefuroxime) was15%.Time to dis-
charge from hospital was analysed using survival analysis
techniques testing for superiority of gemi£oxacin over
ceftriaxone/cefuroxime.
RESULTS
Baseline characteristics
The study was conducted at 46 centres in eight coun-
tries. A total of 274 patients were randomized (138 to
gemi£oxacin and136 to ceftriaxone/cefuroxime) and 272
received at least one dose of studymedication (136 gemi-
£oxacin, 136 ceftriaxone/cefuroxime). Eight patients in
the gemi£oxacin group and16 in the ceftriaxone/cefurox-
ime group withdrew from the study.The most common
reasons for withdrawal were AEs in the gemi£oxacin
group (n = 4), and lost to follow-up (n = 7) and AEs (n = 6)
in the ceftriaxone/cefuroxime group. The demographic
andbaseline clinical characteristics of the clinical ITTpo-
pulation are shown in Table 2 and were similar for the
two treatment groups. The study population (mean age
67.6 years) had relatively severe disease, with over 90%
having apredicted FEV1ofo50%.Fifteenpatients in each
group (10.9% for gemi£oxacin,11.0% for ceftriaxone/cefur-
oxime) hadreceived antibacterial therapyprior to enrol-
ment. A similar proportion of patients in each group
received concomitantmedication (96% for gemi£oxacin,
98% for ceftriaxone) and therewerenomajordi¡erences
inusagebetween the two groups. A total of12 patients in
the gemi£oxacin group and14 in the ceftriaxone/cefurox-
ime group were unsuitable for analysis in the clinical PP
population at the end of therapy and17 and 24 patients,
respectively, in the clinical PP population at follow-up.
Therewere no major di¡erences in the incidence or pat-
tern of exclusions between the two groups. The mostcommon reasons for exclusion from the clinical PP popu-
lationswere treatmentwith another antibacterial, a clin-
ical outcome of unable to determine, medication non-
compliance and co-administration of 430mg predni-
sone per day.Overall compliance with study medication
was 96.4% in the gemi£oxacin group and 95.6% in the cef-
triaxone/cefuroxime group. The baseline characteristics
were similar between the two treatment groups in the
PP population.
Clinical e⁄cacy
Clinical success (primary e⁄cacy parameter) at follow-
up in the clinical PP population was 86.8% (105/121) for
gemi£oxacin and 81.3% (91/112) for ceftriaxone/cefurox-
ime (treatment di¡erence = 5.5; 95% CI 3.9, 14.9)
(Fig.1).Clinical success rates for the clinical ITT popula-
tion at follow-upwere signi¢cantly higher for gemi£oxa-
cin thanceftriaxone/cefuroxime [82.6% (114/138) vs. 72.1%
(98/136), respectively; treatment di¡erence = 10.5; 95%
CI 0.7, 20.4) (Fig.1). At the end of therapy, the clinical suc-
cess rate in the clinical PP populationwas 96.8% (122/126)
with gemi£oxacin comparedwith 94.3% (115/122) for cef-
triaxone/cefuroxime (treatment di¡erence = 2.6; 95% CI
2.6, 7.7). Corresponding clinical success rates for the
clinical ITT population were 92.0% (127/138) for gemi-
£oxacin vs. 88.2% (120/136) for ceftriaxone/cefuroxime
(treatment di¡erence = 3.8; 95% CI3.3,10.8) (Fig.1).
Bacteriological e⁄cacy
A total of 99/274 patients (36.1%) had at least one patho-
gen identi¢ed at screening (48/138 gemi£oxacin, 51/136
ceftriaxone/cefuroxime). Table 3 shows the proportions
of keypathogens identi¢ed in thebacteriology ITTpopu-
lation. The most common pathogen identi¢ed was
H. in£uenzae, present in 30/99 (30.3%) patients, followed
by S. pneumoniae [19/99 (19.2%)] and M. catarrhalis [17/99
(17.2%)].
For the bacteriological ITT population at the end of
therapy, the per-patient bacteriological success rate was
81.3% (39/48) for gemi£oxacin and 82.4% (42/51) for
ceftriaxone/cefuroxime (treatment di¡erence = 1.1;
95% CI 16.3, 14.1). The corresponding results at follow-
up were 62.5% (30/48) for gemi£oxacin vs. 60.8% (31/51)
for ceftriaxone/cefuroxime (treatment di¡erence = 1.7;
95% CI17.4, 20.9).
Overall, a similar number of pathogens in the gemi-
£oxacin group [43/48 (89.6%)] compared with the cef-
triaxone/cefuroxime group [44/51 (86.3%)] were either
eradicated or presumederadicated at the end of therapy
in the bacteriology ITT population. At follow-up, 34/48
(70.8%) in the gemi£oxacin group and 32/51 (62.7%) in
the ceftriaxone/cefuroxime group were either eradi-
cated or presumed eradicated. For the key pathogens
TABLE 2. Baseline clinical and demographic characteristics (clinical ITT population)
Characteristic Treatmentgroup
Gemi£oxacin
N = 138
Ceftriaxone/cefuroxime
N = 136
Gender, male/female 103/35 90/46
Age (years)
Mean7 SD (range) 68.179.84 (42^90) 67.1710.28 (40^92)
Race, n (%)
White 133 (96.4) 133 (97.8)
Duration of chronic bronchitis (years)
Mean7 SD (range) 12.679.46 (2.0^56.0) 11.879.55 (2.0^60.0)
No. of exacerbations duringpast12 months (%)
44 40 (29.0) 46 (33.8)
Current smoker, n (%)
Yes 27 (19.6) 30 (22.1)
Predicted FEV1, n (%)
o50% 127 (92.0) 121 (90.0)
Currentepisode of AECB
Cough, n (%)
Mild 5 (3.6) 7 (5.1)
Moderate 90 (65.2) 89 (65.4)
Severe 43 (31.2) 40 (29.4)
Estimated sputumproduction, n (%)
10mlday1 14 (10.1) 19 (14.0)
41015mlday1 60 (43.5) 55 (40.4)
415mlday1 64 (46.4) 62 (45.6)
Dyspnoea, n (%)
Mild 8 (5.8) 10 (7.4)
Moderate 68 (49.3) 57 (41.9)
Severe 62 (44.9) 69 (50.7)
Fig. 1. Clinicale⁄cacyofgemi£oxacin (&) vs. ceftriaxone/cef-
uroxime (&) at the end of therapy (EOT) and follow-up (FU)
(clinical PP and ITT groups). *Signi¢cant di¡erence in favour of
gemi£oxacin.
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H. in£uenzae, 9/9 S. pneumoniae and 10/11M. catarrhalis
were either eradicated or presumed eradicated at the
end of therapy in the bacteriology ITT population com-
pared with 20/20 H. in£uenzae, 10/10 S. pneumoniae and
6/6 M. catarrhalis in the ceftriaxone/cefuroxime group.
Corresponding results at follow-up for gemi£oxacinwere: 9/10H. in£uenzae, 7/9 S. pneumoniae and 7/11M. cat-
arrhalis, compared with 13/20 H. in£uenzae, 6/10 S. pneu-
moniae and 4/6M. catarrhalis for ceftriaxone/cefuroxime.
The minimum inhibitory concentration (MIC) ranges
of H. in£uenzae, S. pneumoniae andM. catarrhalis isolates
are shown inTable 3.One strain of S. pneumoniae isolated
in the gemi£oxacin group had elevated quinolone MICs:
levo£oxacin48mgml1, o£oxacin416mgml1 and cipro-
£oxacin 432mgml1, though the gemi£oxacin MIC of
0.5mgml1 was at least 32-fold lower. This S. pneumoniae
strain was presumed eradicated and the patient was as-
sessed as a clinical andbacteriological success at follow-up.
Time to hospital discharge
Patients received amean of 4.8 days of gemi£oxacin ther-
apy (88.4% of patients took theirmedication for the pre-
scribed 5 days) compared with 7.8 days of therapy with
ceftriaxone/cefuroxime (31% of patients were treated
for10 days).Themedian time to switch from ceftriaxone
to cefuroximewas 3 days (range,1^4 days). At follow-up
in the clinical ITT group,120/138 (87.0%) of patients in the
gemi£oxacin group had been discharged from hospital
TABLE 3. Number of patients with key respiratory pathogens at screening and MIC ranges of isolates in each therapy group
(bacteriology ITT population)
Pre-therapypathogena Treatmentgroup
Gemi£oxacin
(N = 48)
Ceftriaxone/cefuroxime
(N = 51)
n (%) MICrange (mgml1) n (%) MICrange (mgml1)
Ceftriaxone Cefuroxime
H. in£uenzae 10 (20.8) 0.001^0.015 20 (39.2) 0.015 0.25^4
S. pneumoniae 9 (18.8) 0.015^0.5 10 (19.6) 0.015^0.25 0.012^2
M. catarrhalis 11 (22.9) 0.002^0.008 6 (11.8) 0.015^0.5 0.5^4
aPatients may have hadmore than one pathogen identi¢ed.Other pathogens isolated were Acinetobacter calcoaceticus (n = 1),
Alcaligenes xylosoxidans (n = 1), b-haemolytic streptococcusgroup A (n = 4),Citrobacter freundii (n = 2),Enterobactercloacae (n = 5),
Escherichia coli (n= 7),Haemophilus parain£uenzae (n= 6),Klebsiella pneumoniae (n= 2),Klebsiella spp. (n= 1),Proteusmirabilis (n= 2),
Proteus vulgaris (n = 2), Pseudomonas aeruginosa (n = 9) and Staphylococcus aureus (n = 9).
TABLE 4. Patients reporting adverse experiences sus-
pected or probably related to study medication during on-
therapy to 30 dayspost-therapyperiod (ITT population)
Adverse
experience
Gemi£oxacin
(N = 136)
Ceftriaxone/cefuroxime
(N = 136)
n % n %
Total 15 11.0 8 5.9
Diarrhoea 11 8.1 1 0.7
Abdominalpain 1 0.7 2 1.5
Headache 1 0.7 0 0
Rash 1 0.7 0 0
SGPT increased 1 0.7 0 0
Constipation 0 0 2 1.5
Dyspepsia 0 0 1 0.7
Monoliasis 0 0 1 0.7
Nausea 0 0 1 0.7
Vomiting 0 0 1 0.7
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ime group. For this ITT population, the median time to
hospital dischargewas signi¢cantly less in the gemi£oxa-
cin group (9 days) compared with the ceftriaxone/cefur-
oxime group (11days;P = 0.04,Wilcoxon test).
Safety
Both treatments were generally well tolerated. During
theperiod from commencement to 30 days post-therapy
in the ITT population, 64/136 (47%) patients in the gemi-
£oxacin group and 50/136 (37.0%) in the ceftriaxone/cefur-
oxime group experienced at least one AE of any cause.
The most common AEs reported were diarrhoea in the
gemi£oxacin group [13/136 (9.6%)] and dyspnoea in the
ceftriaxone/cefuroxime group [7/136 (5.1%)].There wereno signi¢cant di¡erences between the two groups in the
incidence or type of AEsreportedbutpotentiallyrelated
adverse drug reactions were identi¢ed by the investiga-
tor in 15/136 (11.0%) patients in the gemi£oxacin group
and 8/136 (5.9%) in the ceftriaxone/cefuroxime group
(Table 4).
In thegemi£oxacingroup,4/136 (2.9%) patients experi-
enced AEs that led to withdrawal compared with 6/136
(4.4%) patients in the ceftriaxone/cefuroxime group:
none were considered by the investigator to be related
to the studymedications.Ninepatients (6.6%) in the gemi-
£oxacin group and 11 (8.1%) in the ceftriaxone/cefurox-
ime group experienced severe AEs, none of which was
consideredby the investigator to be related to the study
medications.Therewere two deaths in each of the treat-
ment groups, none of which were considered to be re-
lated to the studymedications.
There was no di¡erence between the treatment
groups in thenumber of patientswith any clinically signif-
icantchanges invital signs.Nineteenpatients in thegemi-
£oxacin group and 15 in the ceftriaxone/cefuroxime
group had ECGs performedpre-therapy and on-therapy
and no patient in either group had a change in QTc that
was outside the normal range.
DISCUSSION
Patients with risk factors for more severe AECB remain
a challenging population to treat. All of the patients in
the current study were hospitalized. Patients were gen-
erally elderly (mean age 67.6 years), over 90% in either
group had a FEV1ofo50% of predicted (and so most of
the population had exacerbated chronic obstructive pul-
monary disease) and over 30% had experienced more
than four exacerbations in the previous year. Thus, the
overall patient population had relatively severe disease
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presence of co-morbidities and general health status. A
similar proportion of patients in each group (10.9% for gemi-
£oxacin, 11.0% for ceftriaxone/cefuroxime) had received
antibacterial therapy prior to enrolment. Quinolones
are an accepted therapy in the treatment of AECB (11).
However, in severe disease, initial therapy with an i.v.
formulation is usual and studies of oral therapy per-
formed exclusively in hospitalized patients are lacking.
This is the ¢rst report of a large controlled clinical trial
of an oral quinolone in the treatmentof patients hospita-
lized with AECB.This study demonstrated that the clin-
ical e⁄cacy of 5-day oral therapy with gemi£oxacin was
at least as good as that of sequential therapy with i.v. cef-
triaxone/oral cefuroxime (for a maximum of 10 days in
total) in the treatment of hospitalized patients with
AECB.This was shown for both the PP and ITT popula-
tions, with a signi¢cantly higher clinical e⁄cacy for
gemi£oxacin vs. ceftriaxone/cefuroxime in the ITT
population.
Parenteral administration of drugs requires additional
expenditure compared with oral dosing (24). However,
by far the most costly aspect of AECB in hospitalized
patients is the amount of time spent in hospital (2), and
patients receiving i.v. therapymust usually remain hospi-
talized. In this study, the time to hospital discharge was
signi¢cantly less with oral gemi£oxacin than with cef-
triaxone/cefuroxime. Initial treatment with oral gemi-
£oxacin therapy would, therefore, be expected to be
less costly than sequential ceftriaxone/cefuroxime ther-
apy. A full economic analysis of this study is in progress
andwill be reported separately.
Although H. in£uenzae is the major pathogen impli-
cated in AECB, S. pneumoniae is also an important aetio-
logical agent (1). Although quinolone resistance in
S. pneumoniae is still relatively uncommon, concern has
been expressed regarding observations of an increase in
the prevalence of these strains (14). In particular, older
quinolones, such as cipro£oxacin, o£oxacin and levo£ox-
acin, have MIC90s for S. pneumoniae close to the agreed
breakpoints for resistance and questions have been
raisedregarding theuse of these agents in possible pneu-
mococcal infection (25^28). In the current study, a strain
of S. pneumoniae with elevated quinolone MICs (cipro-
£oxacin MIC 432mgml1) was identi¢ed in a patient
who subsequently received gemi£oxacin.The gemi£oxa-
cin MIC of this strainwas 0.5mgml1and treatmentwith
gemi£oxacin resulted in clinical success at follow-up and
this strain was presumed to have been eradicated. This
¢nding is in line with animal studies which have shown
gemi£oxacin to be e¡ective against strains of S. pneumo-
niaewith gemi£oxacin MICs of0.5mgml1 (28).
Both regimens were generally well tolerated and
there were no changes in QTc outside the normal range
in either treatment group for those patients who under-
went ECG recording.This is consistent with a combinedsafety analysis of 137 patients treated with gemi£oxacin
in clinical trials, which found no signi¢cant di¡erence in
QTc prolongation compared with 122 patients treated
with various comparator agents (29).Therewere no sig-
ni¢cant di¡erences in the incidence or type of AEs re-
ported between the two groups, although there was a
numerically higher incidence of diarrhoea in the gemi-
£oxacin group (Table 4).However, all except one episode
of diarrhoeaweremild tomoderate in severity and none
of theAEs considered to be of probable or suspected re-
lationship to studymedication led to withdrawal of a pa-
tient from the study.
In conclusion, oral gemi£oxacin once daily for 5 days
had high clinical and bacteriological e⁄cacy andwaswell
tolerated in the treatment of patients hospitalized with
AECB.Oralgemi£oxacinwas at least clinically equivalent
to i.v. ceftriaxone followed by oral cefuroxime therapy
for a maximum of10 days and resulted in a signi¢cant re-
duction in time to hospital discharge.Gemi£oxacin may
potentially o¡er bene¢ts over standard i.v./oral switch
regimens in terms of cost reduction, increased conveni-
ence to patients and the elimination of the risk of i.v. line
infection.
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